Predictive Technology Group Inc (PRED)

[Don'tDrinkTheKoolAid]

ARTGuide® & Fertility Dx® Commercialization
First Products to Market
• Efficient sales to large, yet highly concentrated market
• 480 assisted reproduction technology (ART) clinics in the U.S.; 80% of market in 6
metro regions
• Self-pay test with no reliance on reimbursement
• 8-10 sales representatives can cover ART market
• Market research based on survey of 20 infertility specialists
• All expressed interest, 1/3 would offer test to 100% of new patients
• Survey indicates average of 35 prescriptions / month / doctor
• Initial targets are 15 larger clinics for clinical research / KOL development
• Assuming conversion of 12 clinics, each with 9 doctors, produces >$150 million in annual revenues
They have test and the treatment!

That's these 2
Diagnostic - ENDORisk® Therapeutic – NHP-07
• Predictive genetic test for
endometriosis covered by key
issued and pending patents
• Incorporates proprietary
endometriosis, pain and
inflammation markers with high
predictive value based on
patented DNA markers
• Proprietary therapeutic for
endometriosis prevention and/or
suppression
• Can be administered prior to
disease development or after
exhibiting initial symptoms to
suppress/delay disease
progression
• Clear regulatory path with
combination of FDA approved
compounds